Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Pamela Bingham

Physician Assistant Byram, MS Physician Assistant

NPI 1427444116 CMS profile 10773279

7275 S Siwell Rd, Byram, MS 39272

Open in the dashboard

General payments

$4,169

201 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pamela Bingham of Byram, MS is reported in the CMS Open Payments database as having received $4,169 across 201 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,273 49
2024 General $1,016 45
2023 General $992 50
2022 General $633 40
2021 General $256 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pamela Bingham
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Pamela Bingham were reported at $1,273. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Pamela Bingham Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $256 $132 $37–$438 $132
2022 $633 $155 $48–$522 $149
2023 $992 $167 $52–$557 $160
2024 $1,016 $178 $55–$600 $164
2025 $1,273 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $778 45 payments
  2. AbbVie, Inc. $703 36 payments
  3. AstraZeneca Pharmaceuticals LP $558 16 payments
  4. Lilly USA, LLC $340 21 payments
  5. GlaxoSmithKline, LLC. $336 19 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $278 16 payments
  7. Inspire Medical Systems, Inc. $186 2 payments
  8. Phathom Pharmaceuticals, Inc. $163 3 payments
  9. Abbott Laboratories $94 5 payments
  10. Supernus Pharmaceuticals, Inc. $92 1 payment
  11. Other $642 37 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,169 201 payments
Products named General payments · program years 2021–2025
  1. PREVNAR 20 $437 21 payments
  2. COMIRNATY $424 20 payments
  3. ABRYSVO $371 16 payments
  4. ELIQUIS $301 21 payments
  5. MOUNJARO $292 18 payments
  6. PAXLOVID $233 17 payments
  7. BREZTRI $227 9 payments
  8. JARDIANCE $212 12 payments
  9. VRAYLAR $208 11 payments
  10. INSPIRE $186 2 payments
  11. Other $2,997 151 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 102 drugs

Part D claims

5,767

Median for Physician Assistant: 241

Drug cost

$267,262

Median for Physician Assistant: $4,110

Branded share of claims

17.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 25 $50,126
Jardiance Empagliflozin Brand 58 $46,172
Eliquis Apixaban Brand 31 $31,686
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 36 $29,780
Linzess Linaclotide Brand 23 $18,968
Mounjaro Tirzepatide Brand 11 $15,601
Januvia Sitagliptin Phosphate Brand 14 $12,956
Symbicort Budesonide/Formoterol Fumarate Brand 24 $5,520
Albuterol Sulfate Hfa Albuterol Sulfate Brand 106 $3,284
Colchicine Generic 32 $2,215

The 10 drugs with the highest cost, of 102 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$83,003

Of which drugs: $11,945

Medicare patients

360

Average age 74

Services billed

2,518

230 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 30%
Chronic kidney disease 22%
Ischemic heart disease 20%
Depression 19%
COPD 16%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 25 25 $7,247
Vaccine for influenza for injection into muscle 90662 Office 58 60 $3,918

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $157
$157 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $156
$156 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $141
$141 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $133
$133 — —
MOUNJARO
  • Lilly USA, LLC $62
$62 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

201 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record